Amarantus, Generex to co-develop MANF-based therapeutic

Under the agreement, MANF-based therapeutic will be developed using Generex’s RapidMist technology in conjunction with oral-insulin spray technology Oral-lyn.

Amarantus chief scientific officer John Commissiong said MANF’s profile of activity indicates that it has significant potential to impact the beta cell dysfunction at the root of impaired insulin secretion in patients leading to clinical diabetes.

"MANF’s ability to correct protein misfolding and mitigate apoptosis may slow or prevent the progression of patients with beta cell dysfunction into full blown diabetes," Commissiong said.